Manufacturer Faces Issues Arising From Acquisition

A manufacturer of over-the-counter (OTC) drugs faced executive compensation, equity compensation and employee benefit issues arising in connection with its acquisition of an Irish corporation in a corporate inversion cash and stock deal valued at approximately $8.6 billion. Our firm represented the manufacturer.

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.